{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:19:59Z","timestamp":1775679599301,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is characterized by bone destruction due to increased bone resorption and decreased bone formation. Semaphorin 4D (CD100, Sema4D) is expressed by osteoclasts, binds to its receptor Plexin-B1, and acts as a mediator of osteoclast\u2013osteoblast interaction that ultimately inhibits osteoblastic bone formation. Preclinical data suggest that Sema4D\/Plexin-B1 pathway is implicated in MM-induced bone disease. However, there is no information on the role of Sema4D in MM patients. Thus, we evaluated Sema4D and Plexin-B1 in six myeloma cells lines in vitro; in the bone marrow plasma (BMP) and serum of 72 newly diagnosed symptomatic MM (NDMM) patients and in 25 healthy controls. Only one myeloma cell line produced high Sema4D. BMP and circulating Sema4D and Plexin-B1 levels were significantly higher in MM patients compared to controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Sema4D correlated with serum calcium levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), increased bone resorption (as assessed by CTX; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), and ISS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There was a trend for higher Sema4D levels in patients with osteolysis (<jats:italic>p<\/jats:italic>\u2009=\u20090.07), while patients with diffuse MRI pattern had higher BMP Sema4D levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). Our data suggest that Sema4D is elevated in MM patients and correlate with adverse myeloma features and increased bone resorption, providing a possible target for novel therapeutic approaches in MM.<\/jats:p>","DOI":"10.1038\/s41408-018-0075-6","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T17:13:17Z","timestamp":1525453997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma"],"prefix":"10.1038","volume":"8","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Bagratuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Bakogeorgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"75_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M. & Dimopoulos, M. A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 8, 7 (2018).","journal-title":"Blood Cancer J."},{"key":"75_CR2","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani, N., Rizzoli, V. & Roodman, G. D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108, 3992\u20133996 (2006).","journal-title":"Blood"},{"key":"75_CR3","doi-asserted-by":"publisher","first-page":"a006718","DOI":"10.1101\/cshperspect.a006718","volume":"2","author":"G Neufeld","year":"2012","unstructured":"Neufeld, G., Sabag, A. D., Rabinovicz, N. & Kessler, O. Semaphorins in angiogenesis and tumor progression. Cold Spring Harb. Perspect. Med. 2, a006718 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"75_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-3-211","volume":"7","author":"U Yazdani","year":"2006","unstructured":"Yazdani, U. & Terman, J. R. The semaphorins. Genome Biol. 7, 211 (2006).","journal-title":"Genome Biol."},{"key":"75_CR5","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/blood-2006-04-014563","volume":"108","author":"A Vacca","year":"2006","unstructured":"Vacca, A. et al. Loss of inhibitory Semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood 108, 1661\u20131667 (2006).","journal-title":"Blood"},{"key":"75_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1210\/me.2007-0363","volume":"22","author":"AL Sutton","year":"2008","unstructured":"Sutton, A. L. et al. Semaphorin 3B is a 1,25-dihydroxyvitamin D3-induced gene in osteoblasts that promotes osteoclastogenesis and induces osteopenia in mice. Mol. Endocrinol. 22, 1370\u20131381 (2008).","journal-title":"Mol. Endocrinol."},{"key":"75_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1042\/BC20040103","volume":"97","author":"G Delorme","year":"2005","unstructured":"Delorme, G., Saltel, F., Bonnelye, E., Jurdic, P. & Machuca-Gayet, I. Expression and function of Semaphorin 7A in bone cells. Biol. Cell 97, 589\u2013597 (2005).","journal-title":"Biol. Cell"},{"key":"75_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4337","volume":"13","author":"T Worzfeld","year":"2014","unstructured":"Worzfeld, T. & Offermanns, S. Semaphorins and plexins as therapeutic targets. Nat. Rev. Drug Discov. 13, 603\u2013621 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"75_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/bonekey.2012.183","volume":"1","author":"T Negishi-Koga","year":"2012","unstructured":"Negishi-Koga, T. & Takayanagi, H. Bone cell communication factors and semaphorins. Bone Rep. 1, 183 (2012).","journal-title":"Bone Rep."},{"key":"75_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ni1553","volume":"9","author":"K Suzuki","year":"2008","unstructured":"Suzuki, K., Kumanogoh, A. & Kikutani, H. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 9, 17\u201323 (2008).","journal-title":"Nat. Immunol."},{"key":"75_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0092-8674(00)80063-X","volume":"99","author":"L Tamagnone","year":"1999","unstructured":"Tamagnone, L. et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99, 71\u201380 (1999).","journal-title":"Cell"},{"key":"75_CR12","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.2489","volume":"17","author":"T Negishi-Koga","year":"2011","unstructured":"Negishi-Koga, T. et al. Suppression of bone formation by osteoclastic expression of Semaphorin 4D. Nat. Med. 17, 1473\u20131480 (2011).","journal-title":"Nat. Med."},{"key":"75_CR13","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1074\/jbc.M706822200","volume":"283","author":"JM Swiercz","year":"2008","unstructured":"Swiercz, J. M., Worzfeld, T. & Offermanns, S. ErbB-2 and met reciprocally regulate cellular signaling via Plexin-B1. J. Biol. Chem. 283, 1893\u20131901 (2008).","journal-title":"J. Biol. Chem."},{"key":"75_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrm1740","volume":"6","author":"RP Kruger","year":"2005","unstructured":"Kruger, R. P., Aurandt, J. & Guan, K. L. Semaphorins command cells to move. Nat. Rev. Mol. Cell Biol. 6, 789\u2013800 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75_CR15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V120.21.1819.1819","volume":"120","author":"E Terpos","year":"2012","unstructured":"Terpos, E. et al. Semaphorin-4D and Plexin-B1 are elevated in multiple myeloma microenvironment and possibly contribute in the development of lytic bone disease. Blood 120, 1819 (2012).","journal-title":"Blood"},{"key":"75_CR16","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood.V128.22.4439.4439","volume":"128","author":"A Suvannasankha","year":"2016","unstructured":"Suvannasankha, A. et al. Regulation of osteoblast function in myeloma bone disease by Semaphorin 4D. Blood 128, 4439 (2016).","journal-title":"Blood"},{"key":"75_CR17","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2017.35.15_suppl.8039","volume":"35","author":"K Lontos","year":"2017","unstructured":"Lontos, K. et al. Semaphorin 4D to suppress bone formation in multiple myeloma. J. Clin. Oncol. 35, 8039 (2017).","journal-title":"J. Clin. Oncol."},{"key":"75_CR18","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.7314\/APJCP.2013.14.10.5883","volume":"14","author":"Y Chen","year":"2013","unstructured":"Chen, Y., Zhang, L., Lv, R. & Zhang, W. Q. Overexpression of Semaphorin 4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer. Asian Pac. J. Cancer Prev. 14, 5883\u20135890 (2013).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"75_CR19","volume":"50","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Regulation of Semaphorin 4D expression and cell proliferation of ovarian cancer by ERalpha and ERbeta. Braz. J. Med. Biol. Res. 50, e6057 (2017).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"75_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie, B. G. & Salmon, S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842\u2013854 (1975).","journal-title":"Cancer"},{"key":"75_CR21","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1200\/JCO.2010.32.5449","volume":"29","author":"E Terpos","year":"2011","unstructured":"Terpos, E., Moulopoulos, L. A. & Dimopoulos, M. A. Advances in imaging and the management of myeloma bone disease. J. Clin. Oncol. 29, 1907\u20131915 (2011).","journal-title":"J. Clin. Oncol."},{"key":"75_CR22","doi-asserted-by":"crossref","unstructured":"Raje, N. et al. An International, Randomized, Double Blind Trial Comparing Denosumab with Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) with Newly Diagnosed Multiple Myeloma [Abstract]. Abstract 546. 16th International Myeloma Workshop (IMW), New Delhi (2017).","DOI":"10.1016\/j.clml.2017.03.047"},{"key":"75_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17474086.2017.1283213","volume":"10","author":"M Gavriatopoulou","year":"2017","unstructured":"Gavriatopoulou, M., Dimopoulos, M. A., Kastritis, E. & Terpos, E. Emerging treatment approaches for myeloma-related bone disease. Expert Rev. Hematol. 10, 217\u2013228 (2017).","journal-title":"Expert Rev. Hematol."},{"key":"75_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bone.2016.08.006","volume":"93","author":"J Dotterweich","year":"2016","unstructured":"Dotterweich, J. et al. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease. Bone 93, 155\u2013166 (2016).","journal-title":"Bone"},{"key":"75_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.beha.2005.01.008","volume":"18","author":"A Dispenzieri","year":"2005","unstructured":"Dispenzieri, A. & Kyle, R. A. Multiple myeloma: clinical features and indications for therapy. Best Pract. Res. Clin. Haematol. 18, 553\u2013568 (2005).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"75_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ejh.12923","volume":"99","author":"F Zagouri","year":"2017","unstructured":"Zagouri, F. et al. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies. Eur. J. Haematol. 99, 409\u2013414 (2017).","journal-title":"Eur. J. Haematol."},{"key":"75_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/jbmr.2322","volume":"30","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y., Wei, L., Miron, R. J., Shi, B. & Bian, Z. Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with Semaphorin 4D expression. J. Bone Miner. Res. 30, 286\u2013296 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"75_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150151","volume":"11","author":"YH Yang","year":"2016","unstructured":"Yang, Y. H. et al. Semaphorin 4D promotes skeletal metastasis in breast cancer. PLoS ONE 11, e0150151 (2016).","journal-title":"PLoS ONE"},{"key":"75_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/2326-6066.CIR-14-0171","volume":"3","author":"EE Evans","year":"2015","unstructured":"Evans, E. E. et al. Antibody blockade of Semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol. Res. 3, 689\u2013701 (2015).","journal-title":"Cancer Immunol. Res."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0075-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:35:11Z","timestamp":1671536111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0075-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0075-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"3 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"42"}}